Key result
In patients with acute myocardial infarction, verapamil reduced the risk of nonfatal reinfarction (RR 0.79; 95% CI 0.65-0.97; p=0.024) and combined death or reinfarction compared with placebo.
Why the study?
Does verapamil reduce mortality or reinfarction in patients with cardiovascular disease?
Meta-Analysis
Does verapamil reduce mortality or reinfarction in patients with cardiovascular disease?
Effect estimate: RR 0.79 (95% CI 0.65-0.97)
p-value: p=0.024
Verapamil reduces the risk of nonfatal reinfarction and the combined outcome of death or nonfatal MI in patients with acute myocardial infarction, with no evidence of harm in angina.
No takes yet. Share an insight, caveat, or question.
Supports verapamil consideration post-AMI for reinfarction prevention; confirms benefit in secondary prevention meta-analysis.
Pepine et al. (1998) conducted a meta-analysis in Cardiovascular disease (acute myocardial infarction, angina, hypertension). Verapamil vs. Placebo was evaluated on Nonfatal reinfarction in patients with acute myocardial infarction (RR 0.79, 95% CI 0.65-0.97, p=0.024). In patients with acute myocardial infarction, verapamil reduced the risk of nonfatal reinfarction (RR 0.79; 95% CI 0.65-0.97; p=0.024) and combined death or reinfarction compared with placebo.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: